ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors ArsenalBio and Bristol Myers Squibb achieve milestone for AB-4000 series as part of a multi-program collaboration to advance next-gen T cell therapies.

ArsenalBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference ArsenalBio CEO Ken Drazan will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 13, 2025, at 4pm PST.